Abstract 1612P
Background
Patient centred outcome measures (PCOMs) are increasingly used to structure proactive symptom assessment and help centre care around the specific needs of the patient. This study aimed to review the use of PCOMs as part of the routine care of inpatients reviewed by the integrated palliative care team in a specialist cancer centre.
Methods
Anonymised electronic palliative care PCOM data were retrieved for inpatients between 7/4/2021 to 31/01/2023, including Integrated Palliative Outcome Scale (IPOS), ECOG performance status, Australian Karnofsky Performance Status (AKPS) and Phase of Illness (POI). Descriptive statistics were used to define the complexity of palliative care needs based on IPOS, PS and POI. The effectiveness of the integrated palliative care service was evaluated by examining the difference between PCOM at initial and follow up assessment.
Results
Digital PCOM records for 1115 episodes of inpatient care were included, of which 391 had follow up data. On initial assessment 63% (703) patients had ECOG PS of 3 or 4 and 77% (864) had AKPS of less than 70. The most prevalent physical symptoms were weakness (84%, 1265), pain (80.7%, 1215), and poor mobility (72.3%, 1089). The most prevalent psychosocial symptom was family or friends feeling anxious or worried (85.8%, 1292). 83% (1250) had at least one palliative care need of severe or overwhelming intensity on initial assessment. 67.5% (753) were in an unstable POI on initial assessment, requiring urgent input. On follow up 92% (328) patients were in a stable, deteriorating or dying POI with no change to the care plan required. In patients with initial moderate to overwhelming symptoms, pain improved in 74%, nausea improved in 84%, vomiting improved in 93%, and constipation improved in 68% at follow up.
Conclusions
The high prevalence of physical and psychosocial symptoms demonstrates the complexity of needs and provides evidence of the requirement for integration of specialist palliative care services in cancer centres. The improvement in symptom scores between initial and follow up assessment demonstrates the effectiveness of integrated palliative care for cancer centre inpatients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05